Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469570 | 1.00 | MAPKAPK2 (0.40) | MAPKAPK2MAP4K4LCKCA1CA12 | |
| SCHEMBL7416577 | 0.85 | LCK (0.45) | MAPKAPK2LCKCA1CA12CA9 | |
| SCHEMBL6517445 | 0.84 | MAPKAPK2 (0.40) | MAPKAPK2MAP4K4LCKCA1SYK | |
| SCHEMBL31430396 | 0.83 | MAPKAPK2 (0.41) | MAPKAPK2MAP4K4CA1SYKATR | |
| SCHEMBL29477633 | 0.83 | ALDH1A1 (0.40) | MAPKAPK2MAP4K4CA1SYKATR | |
| SCHEMBL24367667 | 0.83 | ALDH1A1 (0.40) | MAPKAPK2MAP4K4CA1SYKATR | |
| SCHEMBL24364867 | 0.83 | MAPKAPK2 (0.41) | MAPKAPK2MAP4K4CA1SYKATR | |
| SCHEMBL7412985 | 0.82 | SYK (0.42) | MAPKAPK2LCKCA1CA12CA9 | |
| SCHEMBL1181471 | 0.82 | AAK1 (0.51) | LCKCA1CA12CA9ATR | |
| SCHEMBL24366932 | 0.82 | LMNA (0.40) | MAPKAPK2MAP4K4SYKATRPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| CN-101808996-A | Nicotinamide derivatives, their preparation and their use in therapeutics | SANOFI AVENTIS | 2010-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPKAPK2 4853/4885MAP4K4 4660/4885LCK 3675/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPKAPK2 4853/4885MAP4K4 4660/4885LCK 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.